{
    "organizations": [],
    "uuid": "02c32c52fbe6d698cda2da8e773268c2ecd2b5ac",
    "author": "",
    "url": "https://www.reuters.com/article/brief-pfizer-canada-says-besponsa-approv/brief-pfizer-canada-says-besponsa-approved-by-health-canada-for-treating-adults-with-a-type-of-leukemia-idUSFWN1RJ0GN",
    "ord_in_thread": 0,
    "title": "BRIEF-Pfizer Canada Says BESPONSA Approved By Health Canada For Treating Adults With A Type Of Leukemia",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 6, 2018 / 7:06 PM / Updated 11 minutes ago BRIEF-Pfizer Canada Says BESPONSA Approved By Health Canada For Treating Adults With A Type Of Leukemia Reuters Staff 1 Min Read \nApril 6 (Reuters) - Pfizer Canada Inc: \n* PFIZER CANADA SAYS BESPONSA APPROVED BY HEALTH CANADA FOR TREATING ADULTS WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA Source text for Eikon: Further company coverage:",
    "published": "2018-04-06T22:06:00.000+03:00",
    "crawled": "2018-04-06T22:29:16.003+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "canada",
        "say",
        "besponsa",
        "approved",
        "health",
        "canada",
        "treating",
        "adult",
        "type",
        "leukemia",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "pfizer",
        "canada",
        "inc",
        "pfizer",
        "canada",
        "say",
        "besponsa",
        "approved",
        "health",
        "canada",
        "treating",
        "adult",
        "relapsed",
        "refractory",
        "precursor",
        "acute",
        "lymphoblastic",
        "leukemia",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}